Pharsight

1. Drug name - BRUKINSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447106	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)
US10570139	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)
US11142528	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)
US10927117	BEIGENE	Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof	Aug, 2037 (14 years from now)
CN104884458A	BEIGENE	Fused Ring Compound As A Protein Kinase Inhibitor	Apr, 2033 (10 years from now)
CN104884458B	BEIGENE	Fused Heterocyclic Compounds As Protein Kinase Inhibitors	Apr, 2033 (10 years from now)
IN201503521P2	BEIGENE	Fused Heterocyclic Compounds As Protein Kinase Inhibitors	Apr, 2034 (11 years from now)
IN370291B	BEIGENE	Fused Heterocyclic Compounds As Protein Kinase Inhibitors	Apr, 2034 (11 years from now)
EP2989106B1	BEIGENE	Fused Heterocyclic Compounds As Protein Kinase Inhibitors	Mar, 2042 (19 years from now)
EP2989106A1	BEIGENE	Fused Heterocyclic Compounds As Protein Kinase Inhibitors	Mar, 2042 (19 years from now)
EP2989106A4	BEIGENE	Fused Heterocyclic Compounds As Protein Kinase Inhibitors	Mar, 2042 (19 years from now)

Drugs and Companies using ZANUBRUTINIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
80MG	CAPSULE;ORAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.